Centers for Medicare & Medicaid Services Intend to Reimburse Visudyne® with Occult and Minimally Classic Lesions in AMD
East Hanover, New Jersey and Vancouver, British Columbia, January 29, 2004 - Novartis Pharma AG, Ophthalmics, the eye health unit of Novartis AG (NYSE: NVS) and QLT Inc. (NASDAQ: QLTI; TSX: QLT), announced that the Centers for Medicare & Medicaid Services (CMS) has determined the evidence supports reimbursement for patients treated with Visudyne® (verteporfin) for age-related macular degeneration (AMD) with occult and minimally classic lesions that are four discs areas or less in size and have evidence of recent disease progression. Medicare already offers coverage for Ocular Photodynamic Therapy (OPT) in AMD with predominantly classic lesions.
Please see full press release under the following link:
